FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

PANACEABIO

352.9
-5.35 (-1.49%)
Updated 03:28 23/07 IST

PANACEABIO Buy or Sell - FrontPage Forums

1 Users have submitted 2 trade ideas of Rs. 5,402.2 for PANACEABIO
Disclaimer
100% Bullish
0% Bearish

PANACEABIO Buy or Sell - Brokerage Reports

No. of reports in last year
0
No. of analysts
0
Average Consensus Forecast
Consensus Potential
0.00%
See PANACEABIO Share Price Targets >>

PANACEABIO Ratings

Long term PANACEABIO rating by FrontPage users
0/5 (0 Ratings)0
Find answers to all your questions on live PANACEABIO message board: Is PANACEABIO buy or sell? Should I buy PANACEABIO shares? Why are PANACEABIO shares falling? Should I invest in PANACEABIO stock?

  1. Home
  2. PANACEABIO Forum

PANACEABIO Share Price Discussion

Like
Reply
N
Reputation: 15,563 • Jul 14 1:26 AM
Serum Institute to begin Sputnik V manufacturing from September
With their import approved by the Drug Controller General of India (DCGI), the cultivation process has begun, RDIF, which is promoting the vaccine globally, said in a statement.
The Economic Times
Like
Reply

Type
Sell
Instrument
PANACEABIO
Entry Price
₹398
Price@Trade
₹398
Target Price
₹305
Stop Price
₹410
Valid Till
Jul 5, 2021 3:20 AM
Margin
₹398 approx for 1 Qty
Status
Validity Over
Exit Price
₹397.4
Net P&L
+₹0.6 (+0.15%)
Like
Reply (1)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Jul 5 8:50 AM

Update
Validity Over
Exit Price
₹397.4
Net P&L
+₹0.6 (+0.15%)
N
Reputation: 15,563 • Jul 5 5:36 AM
Panacea Biotec jumps 9% on manufacturing licence for Sputnik V vaccine
Panacea Biotec said on Sunday the Indian drugs regulator granted the licence following the company's collaboration with the Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund which markets the shot internationally.
The Economic Times
Like
Reply
Like
Reply

Type
Buy
Instrument
PANACEABIO
Entry Price
₹405.5
Price@Trade
₹405
Target Price
₹420
Stop Price
₹402
Valid Till
Aug 5, 2021 3:20 AM
Margin
₹40,550 approx for 100 Qty
Status
Exited before entry

Like
Reply (1)
swap_vert
Trade
See all replies
Gaikwad @gaikwad-ryuEvus5O
Jul 5 2:50 AM

Update
Exited before entry
Price @ Update
₹404.5

Panacea Biotech - Cmp 378
Stoploss 362
Target 🎯 475 - 576
Like
Reply (2)
See all replies

Freeze

Bro,I entered waterbase at 140.25 today..is that ok..also shoppers stop at 243..please adivise bro

#PANACEABIO Announces Reciept of Manufacturing Licence to produce Sputnik V vaccine at Baddi , Himachal Pradesh.
Like
Reply

📌 Today's Buzzing Cash Stocks...
02/07/2021
#DIXON - Approval under PLI for IT hardware
#REDINGTON - Approval under PLI for IT hardware
#AFFLE - Aquisition of Jampp company
#HAPPSTMNDS - Brokerage Report
#PANACEABIO - Brokerage Report
Stock Research Yogi
Like
Reply
Like
Reply
V
Reputation: 48 • Jun 10 6:14 AM

Type
Buy
Instrument
PANACEABIO
Entry Price
₹376.55
Price@Trade
₹376.55
Target Price
₹474.95
Stop Price
₹359.95
Valid Till
Jun 10, 2022 3:20 AM
Margin
₹320,067.5 approx for 850 Qty
Status
Exited
Exit Price
₹374
Net P&L
-₹2,167.5 (-0.68%)

Like
Reply (1)
swap_vert
Trade
See all replies
Vivek  @vivek001
Jun 10 6:48 AM

Update
Exited
Exit Price
₹374
Net P&L
-₹2,167.5 (-0.68%)
N
Reputation: 5,262 • Jun 10 5:12 AM
Like
Reply (1)
See all replies
Neeraj Puri Goswami @neeraj
Jun 10 5:49 AM

#PANACEABIO suggested at 374. now touched 379. Congrats !!
N
Reputation: 15,563 • Jun 4 11:46 AM
COVID-19: Delhi High Court anguished over shortage of vaccines in India
The high court was deliberating with the issue related to manufacturing of COVID vaccine Sputnik V by India's Panacea Biotec in collaboration with Russian Direct Investment Fund (RDIF).
The Economic Times
Like
Reply
T
Reputation: 36,551 • Jun 3 2:02 AM

Stocks in News
Panacea Biotec: The company reported consolidated loss at Rs 54.14 crore in Q4FY21 against Rs 68.39 crore in Q4FY20, revenue rose to Rs 168.27 crore from Rs 125.36 crore YoY.
Muthoot Finance: The company reported higher consolidated profit at Rs 1,023.76 crore in Q...
Read more...
2
Reply
N
Reputation: 15,563 • Jun 2 4:21 AM
Panacea Biotec posts loss of Rs 54 cr in Q4
Shares of Panacea Biotec closed at Rs 415.30 per scrip on BSE, up 0.12 percent from its previous close.
The Economic Times
Like
Reply
N
Reputation: 15,563 • Jun 2 2:11 AM
Officers sitting on untapped vaccine manufacturing potential need to be charged with manslaughter, says High Court
The court said the Centre should expedite the process of clearing samples of Panacea Biotec which has collaborated with Russian Direct Investment Fund (RDIF) for manufacturing Sputnik V here.
The Economic Times
Like
Reply

𝐂𝐚𝐬𝐡 𝐒𝐭𝐨𝐜𝐤𝐬 𝐢𝐧 𝐅𝐨𝐜𝐮𝐬 (2𝐧𝐝 𝐉𝐮𝐧𝐞)
#BALRAMCHIN
#SUZLON
#NEOGEN
#UNIONBANK
𝑺𝒕𝒐𝒄𝒌 𝑹𝒆𝒔𝒆𝒂𝒓𝒄𝒉 𝒀𝒐𝒈𝒊
Like
Reply
N
Reputation: 15,563 • Jun 2 1:06 AM
Stocks in news: ITC, Infosys, PVR, MTAR Tech, SBI, Panacea Biotec and Radico Khaitan
Panacea Biotec, NRB Bearings, Dhunseri Ventures, Lyka Labs, Jenburkt Pharmaceuticals and Burnpur Cement are among companies that will announce their March quarter results today.
The Economic Times
Like
Reply

PANACEABIO - chart - 3271887
#PANACEABIO LONG TERM BUY MODE TGT 796 SL 326(MONTHLY CLBS)
1
Reply

Type
Buy
Instrument
PANACEABIO
Entry Price
₹440
Price@Trade
₹445
Target Price
₹590
Stop Price
₹400
Valid Till
May 27, 2022 3:20 AM
Margin
₹22,000 approx for 50 Qty
Status
Exited before entry
Like
Reply (1)
swap_vert
Trade
See all replies
Pallavi Dutta @pallavidutta
May 27 5:46 AM

Update
Exited before entry
Price @ Update
₹445
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 2,00,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • PANACEABIO - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization1,214.97
    Enterprise Value1,365.11
    Price to Earnings656.61
    Price to Book Value2.91
    Return on Capital Employed0.03
    Return on Equity-0.19
    Face Value1
    Dividend YieldNA
  • PANACEABIO - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    27-Nov-17Rudra Shares & Stocks BrokersBuy310
    PANACEABIO Brokerage Price Target
  • PANACEABIO Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Jul 23362.9362.9352353.5
    Jul 22343.45360343.45358.25
    Jul 20351.3353.9340343.45
    Jul 19355362.8349351.3
    Jul 16369.45369.45356.2358.85
  • PANACEABIO Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹370.83
    30 Day Moving Average₹374.28
    50 Day Moving Average₹382.58
    100 Day Moving Average₹316.46
    200 Day Moving Average₹261.33
  • PANACEABIO - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue577530.090.09
    Operating Profit8223.492.49
    Profit Before Tax-61-83.78-0.27
    Net Income-72-86.25-0.17
  • PANACEABIO - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds4183780.11
    Total Liabilities1,0241,482-0.31
    Total Assets1,4421,860-0.22
  • PANACEABIO - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity172115.860.48
    Cash from Investing Activity-3-32.18-0.91
    Cash from Financing Activity-164-87.20.88
    Net Cash Flow6-3.52-2.7
  • PANACEABIO - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets-0.04-0.05
    Return on Equity-0.19-1.27
    Return on Capital Employed0.030.02
  • PANACEABIO - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue-0.15
    3 Year CAGR Growth in Operating Profit0.21
    3 Year CAGR Growth in EBIDTA0.04
    3 Year CAGR Growth in Net Income-0.1
    3 Yr CAGR Growth - Diluted EPS-0.1
  • PANACEABIO - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue-0.03
    5 Year CAGR Growth in Operating Profit1.98
    5 Year CAGR Growth in EBIDTA2.61
    5 Year CAGR Growth in Net Income0.69
    3 Yr CAGR Growth - Diluted EPS0.69
  • PANACEABIO - Recent News

    keyboard_arrow_down
    NewsBot
    Jul 14 1:26 AM
    Serum Institute to begin Sputnik V manufacturing from September
    The Economic Times
    NewsBot
    Jul 5 5:36 AM
    Panacea Biotec jumps 9% on manufacturing licence for Sputnik V vaccine
    The Economic Times
    NewsBot
    Jun 4 11:46 AM
    COVID-19: Delhi High Court anguished over shortage of vaccines in India
    The Economic Times
    NewsBot
    Jun 2 4:21 AM
    Panacea Biotec posts loss of Rs 54 cr in Q4
    The Economic Times
    NewsBot
    Jun 2 2:11 AM
    Officers sitting on untapped vaccine manufacturing potential need to be charged with manslaughter, says High Court
    The Economic Times
    NewsBot
    May 25 4:11 AM
    Panacea Biotec soars 5% as production of Sputnik V kicks off
    The Economic Times
    NewsBot
    May 24 11:56 AM
    COVID-19: Sputnik V production starts in India; 100 million doses to be produced annually
    The Economic Times
    NewsBot
    May 20 4:56 AM
    Prices of Sputnik V COVID-19 vaccine may drop after local manufacturing begins: Dr Reddy's
    The Economic Times
    NewsBot
    May 17 12:01 PM
    Adar Poonawalla transfers entire Panacea Biotec stake to Serum Institute
    The Economic Times
    NewsBot
    May 17 8:21 AM
    Panacea Biotec files suit against Sanofi for patent infringement
    The Economic Times
  • PANACEABIO - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Cipla Ltd. NSE: CIPLA | BSE: 500087 |...
    Aurobindo Pharma Ltd. NSE: AUROPHARMA...
    Biocon Ltd. NSE: BIOCON | BSE: 532523...
    Lupin Ltd. NSE: LUPIN | BSE: 500257 |...
    Dr. Reddy's Laboratories Ltd. NSE: DR...
    Glenmark Pharmaceuticals Ltd. NSE: GL...
    Divi's Laboratories Ltd. NSE: DIVISLA...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Cadila Healthcare Ltd. NSE: CADILAHC ...
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.

PrivacyTerms
FrontPage © 2020